A federal judge in Delaware has overturned a jury’s verdict requiring Gilead Sciences Inc to pay a record $2.54 billion because its hepatitis C drugs Sovaldi and Harvoni infringed a patent held by rival Merck & Co Inc.

An 8-week course of sofosbuvir/ledipasvir (Harvoni) led to a sustained response in all people with HIV and genotype 1 or 4 hepatitis C virus (HCV) in the SWIFT-C study, according to a report at the AASLD Liver Meeting last month in Washington, DC.

Currently most effective directly-acting antiviral agent for hepatitis C (HCV) treatment has already arrived to Ukraine! Alliance for Public Health launches the third phase of HCV treatment program for key populations. This phase stipulates using a direct-acting antiviral agent, which is new for Ukraine – Harvoni ...

People who inject drugs (PWID) can have an excellent response to sofosbuvir-based therapy for hepatitis C virus (HCV) infection, Ukrainian research presented to the recent 2016 AASLD Liver Meeting shows. Overall, 93% of people had a sustained virological response 12 weeks (SVR12) after the completion of ...